T. Rowe Price holds 7.7% of Vera Therapeutics (VERA) common stock
Rhea-AI Filing Summary
T. Rowe Price Associates, Inc. reports beneficial ownership of 5,461,988 shares of Vera Therapeutics common stock, representing 7.7% of the class as of December 31, 2025. It has sole voting power over 5,376,319 shares and sole dispositive power over 5,461,976 shares, with no shared voting or dispositive power.
The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
Positive
- None.
Negative
- None.